CYTOSORBENTS CORPORATION (NASDAQ:CTSO) Files An 8-K Results of Operations and Financial Condition
Item 2.02
On March 7, 2019, CytoSorbents Corporation (the Company) filed its Annual Report on Form 10-K reporting its financial results for the fourth quarter and twelve months ended December 31, 2018. The Company also issued a press release on March 7, 2019 announcing its financial results for the period ended December 31, 2018. A copy of the press release is furnished herewith as Exhibit 99.1.*
| 99.1 | CytoSorbents Corporation Press Release, dated March 7, 2019. |
* The information in Item 2.02 of this Form8-K shall not be deemed filed for purposes of Section18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Cytosorbents Corp Exhibit
EX-99.1 2 tv516063_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CytoSorbents Achieves Record Revenue and Product Sales Growth in 2018 2018 Total Revenue was $22.5 million,…
To view the full exhibit click here
About CYTOSORBENTS CORPORATION (NASDAQ:CTSO)
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.
